Induction of immune-modulated opportunistic tumours and a new strategy for their treatment. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Induction of immune-modulated opportunistic tumours and a new strategy for their treatment.

Int J Immunotherapy; 7(4):189-95 1991. Unique Identifier : AIDSLINE ICDB/93690155
Madarnas P; Dube M; Nigam VN; Dept. of Pathology, Univ. of Sherbrooke, Sherbrooke, Quebec, J1H; 5N4, Canada

Abstract: Dimethylhydrazine treatment of CD1 mice for more than 30 wk induced colorectal-anal cancer as well as skin and visceral angiosarcomas in high proportions. These mice were tested as models for AIDS-associated Kaposi's sarcoma (KS) with respect to their immune status and for the histological similarity of skin lesions with KS. The mice exhibited a 60% decrease in antibody response to sheep RBC, a 50% decrease in the mitogenic response of spleen cells to LPS, as well as splenomegaly. The number of T-cell subsets in spleen and peripheral blood remained unchanged. There was a striking similarity between the histological appearance of skin tumors and KS. Tumor-bearing mice were subjected to antiangiogenic therapy consisting of a cortisone and maltose tetrapalmitate combination which prevented tumor vol increase. (12 Refs)
Keywords: Animal Antineoplastic Agents/THERAPEUTIC USE Anus Neoplasms/BLOOD SUPPLY/IMMUNOLOGY/*THERAPY Colorectal Neoplasms/BLOOD SUPPLY/IMMUNOLOGY/*THERAPY Cortisone/*THERAPEUTIC USE Disease Models, Animal Glycolipids/*THERAPEUTIC USE Immunotherapy Lymphoma, Non-Hodgkin's/IMMUNOLOGY/*THERAPY Mice Neovascularization, Pathologic Sarcoma, Kaposi's/BLOOD SUPPLY/IMMUNOLOGY/*THERAPY T-Lymphocytes/IMMUNOLOGY JOURNAL ARTICLEKWDanimalantineoplasticagents/therapeuticuseanusneoplasms/bloodsupply/immunology/KWDtherapycolorectalneoplasms/bloodsupply/immunology/KWDtherapycortisone/KWDtherapeuticusediseasemodels,animalglycolipids/KWDtherapeuticuseimmunotherapylymphoma,non-hodgkin's/immunology/KWDtherapymiceneovascularization,pathologicsarcoma,kaposi's/bloodsupply/immunology/KWDtherapyt-lymphocytes/immunologyjournalarticle
930430
M9340815

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .